Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Hum Vaccin Immunother ; 19(1): 2199656, 2023 12 31.
Article in English | MEDLINE | ID: covidwho-2292007

ABSTRACT

The coronavirus disease (COVID-19) threat is subsiding through extensive vaccination worldwide. However, the pandemic imposed major disruptions in global immunization programs and has aggravated the risks of vaccine-preventable disease (VPD) outbreaks. Particularly, lower-middle-income regions with minimal vaccine coverage and circulating vaccine-derived viral strains, such as polio, suffered additional burden of accumulated zero-dose children, further making them vulnerable to VPDs. However, there is no compilation of routine immunization disruptions and recovery prospects. There is a noticeable change in the routine vaccination coverage across different phases of the pandemic in six distinct global regions. We have summarized the impact of COVID-19 on routine global vaccination programs and also identified the prospects of routine immunization to combat COVID-like outbreaks.


Subject(s)
COVID-19 , Vaccines , Child , Humans , Pandemics/prevention & control , COVID-19/epidemiology , COVID-19/prevention & control , Immunization Schedule , Vaccination , Immunization Programs
2.
Hum Vaccin Immunother ; 16(9): 2217-2218, 2020 09 01.
Article in English | MEDLINE | ID: covidwho-532659

ABSTRACT

The coronavirus disease (COVID-19) is resulting in millions of infected individuals with several hundred thousands dead throughout the world. Amidst all the havoc, one interesting observation in the present COVID-19 pandemic is the negligible symptoms in the young; particularly children below 10 years of age. We assume the extensive pediatric vaccination with MMR vaccines followed globally could have resulted in innate immune responses, e.g., induction of interferons (IFNs) and activated natural killer (NK) cells, thereby offering natural immunity against SARS-CoV-2 in the young population. Possible cross-protective innate immunity offered by MMR vaccination prompted us to suggest repurposing MMR vaccination for immuno-prophylaxis against COVID-19.


Subject(s)
Coronavirus Infections/prevention & control , Drug Repositioning , Measles-Mumps-Rubella Vaccine/administration & dosage , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Betacoronavirus , COVID-19 , Child , Coronavirus Infections/epidemiology , Cross Protection , Cytokine Release Syndrome/epidemiology , Cytokine Release Syndrome/prevention & control , Humans , Interferons/immunology , Killer Cells, Natural/immunology , Measles-Mumps-Rubella Vaccine/immunology , Pneumonia, Viral/epidemiology , Prevalence , SARS-CoV-2 , Vaccination
SELECTION OF CITATIONS
SEARCH DETAIL